Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Biomed Research International|October 4, 2013
A prospective profile of visual field loss following stroke: prevalence, type, rehabilitation, and outcomeFiona J Rowe, David Wright, Darren Brand, et al.
The Journal of Membrane Biology|June 22, 2007
A deafness-associated mutant human connexin 26 improves the epithelial barrier in vitroY K Stella Man, Caroline Trolove, Daniel Tattersall, et al.
European Journal of Pharmacology|March 31, 2006
SB-649915, a novel, potent 5-HT1A and 5-HT1B autoreceptor antagonist and 5-HT re-uptake inhibitor in native tissueClaire Scott, Ellen M Soffin, Matthew Hill, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 6, 2023
USP16 is an ISG15 cross-reactive deubiquitinase that targets pro-ISG15 and ISGylated proteins involved in metabolismJin Gan, Adán Pinto-Fernández, Dennis Flierman, et al.
Heart Rhythm|May 1, 2022
Clinical outcomes and predictors of complications in patients undergoing leadless pacemaker implantationFaris Haddadin, Monil Majmundar, Ahmad Jabri, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|May 26, 2011
Reading difficulty after stroke: ocular and non ocular causesFiona Rowe, David Wright, Darren Brand, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|August 31, 2007
In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant): potential therapeutic utility in the treatment of schizophreniaLee A Dawson, Katherine J Cato, Claire Scott, et al.
Elife|November 10, 2020
Rationally derived inhibitors of hepatitis C virus (HCV) p7 channel activity reveal prospect for bimodal antiviral therapyJoseph Shaw, Rajendra Gosain, Monoj Mon Kalita, et al.
British Journal of Cancer|November 20, 2020
Deletion of the deISGylating enzyme USP18 enhances tumour cell antigenicity and radiosensitivityAdan Pinto-Fernandez, Mariolina Salio, Tom Partridge, et al.
Plos Pathogens|August 12, 2020
Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenzaClaire Scott, Jayakanth Kankanala, Toshana L Foster, et al.
Pageof 5